IFNG and cancer: Combination of IFN-γ treatment with IDO1 inhibitors is a promising new cancer immunotherapeutic strategy that effectively enhances antitumor immunity and eliminates TRCs (i.e., stem cell-like cancer cells that are self-renewing, highly tumorigenic, and can repopulate tumors).